Skip to main content
Top
Published in: Drug Safety 2/2012

01-02-2012 | Short Communication

Selected National Pharmacovigilance Websites

An Analysis of Contents

Authors: Dr Charlotte I.S. Barker, John C.C. Talbot, Jeffrey K. Aronson

Published in: Drug Safety | Issue 2/2012

Login to get access

Abstract

Background: Pharmacovigilance involves the detection, assessment, understanding, and prevention of adverse drug reactions (ADRs), nationally and internationally. Effective communication, which relies increasingly on the Internet, is a crucial aspect of pharmacovigilance activities.
Aim: The aim of this study was to perform an exploratory survey of national pharmacovigilance websites and compare their contents.
Methods: Of 99 international pharmacovigilance organizations known to us (listed in the Side Effects of Drugs Annual 30), 45 included website addresses and 35 provided some or all of the information in English. We reviewed 10 of these 35 websites in order to identify their contents. The 10 sites that we selected contained the most extensive information on pharmacovigilance of those that we were able to access. Reviewing these sites, we identified 32 items of information that we used to assess the scope of each website systematically, using a scoring system based on the presence or absence of those items.
Results: All the websites gave clear descriptions of national pharmacovigilance requirements and the reporting systems for ADRs, and all included devices. Beyond this, there was great variability in content from site to site. Few websites allowed access to raw pharmacovigilance data, such as individual case reports.
Conclusions: Online drug safety communication from the selected national websites we examined is highly variable from site to site, although a wider study is needed to confirm this. Agreement on the key components of pharmacovigilance websites would facilitate the development of a standardized format to improve online communication.
Literature
4.
go back to reference Kim P, Eng TR, Deering MJ, et al. Published criteria for evaluating health related web sites: review. BMJ 1999; 318(7184): 647–9PubMedCrossRef Kim P, Eng TR, Deering MJ, et al. Published criteria for evaluating health related web sites: review. BMJ 1999; 318(7184): 647–9PubMedCrossRef
6.
go back to reference Vitry A, Lexchin J, Sasich L, et al. Provision of information on regulatory authorities’ websites. Intern Med J 2008; 38(7): 559–67PubMedCrossRef Vitry A, Lexchin J, Sasich L, et al. Provision of information on regulatory authorities’ websites. Intern Med J 2008; 38(7): 559–67PubMedCrossRef
7.
go back to reference World Health Organization. Optimization of medicines regulatory authority web sites. WHO Drug Inf 2010; 24(2): 91–8 World Health Organization. Optimization of medicines regulatory authority web sites. WHO Drug Inf 2010; 24(2): 91–8
8.
go back to reference Anton C, Cox AR, Coleman JJ, et al. A comparison of publicly available spontaneous adverse drug reaction data from national spontaneous reporting schemes [abstract]. Drug Saf 2006; 29(10): 914 Anton C, Cox AR, Coleman JJ, et al. A comparison of publicly available spontaneous adverse drug reaction data from national spontaneous reporting schemes [abstract]. Drug Saf 2006; 29(10): 914
9.
go back to reference Uppsala Monitoring Centre. Address list of national centers that participate in the WHO drug monitoring programme. In: Aronson JK, editor. Side effects of drugs annual 30. Amsterdam: Elsevier, 2008: 582–95 Uppsala Monitoring Centre. Address list of national centers that participate in the WHO drug monitoring programme. In: Aronson JK, editor. Side effects of drugs annual 30. Amsterdam: Elsevier, 2008: 582–95
11.
go back to reference Hauben M, Aronson JK. Defining ‘signal’ and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf 2009; 32(2): 99–110PubMedCrossRef Hauben M, Aronson JK. Defining ‘signal’ and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf 2009; 32(2): 99–110PubMedCrossRef
12.
go back to reference Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf 2005; 28(10): 851–70PubMedCrossRef Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf 2005; 28(10): 851–70PubMedCrossRef
14.
go back to reference Medawar C, Herxheimer A. A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behaviour with paroxetine. Int J Risk Saf Med 2003/2004; 16: 5–19 Medawar C, Herxheimer A. A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behaviour with paroxetine. Int J Risk Saf Med 2003/2004; 16: 5–19
16.
go back to reference Loke YK, Derry S, Price D, et al. Case reports of suspected adverse drug reactions: systematic literature survey of follow-up. BMJ 2006; 332: 335–9PubMedCrossRef Loke YK, Derry S, Price D, et al. Case reports of suspected adverse drug reactions: systematic literature survey of follow-up. BMJ 2006; 332: 335–9PubMedCrossRef
Metadata
Title
Selected National Pharmacovigilance Websites
An Analysis of Contents
Authors
Dr Charlotte I.S. Barker
John C.C. Talbot
Jeffrey K. Aronson
Publication date
01-02-2012
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 2/2012
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/11596270-000000000-00000

Other articles of this Issue 2/2012

Drug Safety 2/2012 Go to the issue